Regulation of DNA damage response and cell cycle in radiation-resistant HL60 myeloid leukemia cells

Hazawa, Masaharu; Hosokawa, Yoichiro; Monzen, Satoru; Yoshino, Hironori; Kashiwakura, Ikuo

doi:10.3892/or.2012.1771

Cited by 9 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Radiation resistance of tumors is a complex phenomenon, involving complex molecular mechanisms and genetic alterations. DNA damage is the main mechanism by which radiotherapy-induced cell death occurs, including single and double strand breaks, and base damage (50,53–55). Ionizing radiation can provide sufficient time to repair damaged DNA and enable cells to survive via cell cycle arrest; however, when DNA repair fails, apoptosis is induced, an important defense and protection mechanism for the maintenance of genomic stability in normal cells.…”

Section: Discussionmentioning

confidence: 99%

MiRNA‑30a‑3p inhibits metastasis and enhances radiosensitivity in esophageal carcinoma by targeting insulin‑like growth factor 1 receptor

et al. 2019

View full text Add to dashboard Cite

It has been demonstrated that microRNAs (miRNAs) serve important roles in various biological processes, such as tumorigenesis. In the present study, the role of miR-30a-3p in the pathogenesis of esophageal carcinoma (EC) was investigated. Reverse transcription-quantitative polymerase chain reaction was performed to determine the levels of miR-30a-3p expression in EC tissues and cell lines. Then, the effects of miR-30a-3p on the migration, invasion and radiosensitivity of EC cells were investigated using scratch-wound, Transwell and radiosensitivity assays, respectively. A dual-luciferase reporter assay was performed to determine potential interactions between miR-30a-3p and the 3′-untranslated region (3′-UTR) of insulin-like growth factor 1 receptor (IGF-1R). The results demonstrated that the levels of miR-30a-3p expression in EC tissues and cell lines were significantly decreased compared with those in paired healthy tissues and a human esophageal epithelial cell line. Upregulation of miR-30a-3p expression significantly suppressed migration, invasion and epithelial-mesenchymal transition (EMT), and enhanced radiosensitivity in EC cells. Analysis of luciferase activity demonstrated that miR-30a-3p interacted with the 3′-UTR of IGF-1R, and knockdown of IGF-1R induced similar effects on the migration, invasion, EMT and radiosensitivity of EC cells. The results indicated that miR-30a-3p suppressed metastasis and enhanced the radiosensitivity of EC cells via downregulation IGF-1R, suggesting that miR-30a-3p may be a potential therapeutic target in the treatment of EC.

show abstract

Section: Discussionmentioning

confidence: 99%

MiRNA‑30a‑3p inhibits metastasis and enhances radiosensitivity in esophageal carcinoma by targeting insulin‑like growth factor 1 receptor

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Mūsų rezultatai sutapo su šia studija, kurioje buvo nustatyta, kad plaučių vėžio radioatspariose ląstelėse po radioterapijos poveikio praėjus 24 valandoms G2/M fazėje ląstelių kiekis buvo didesnis, lyginant su radiojautriomis ląstelėmis [26]. Panašus tyrimas buvo atliktas ir su mieloidinės leukemijos ląstelėmis, kur M. Hazawa su kolegomis nustatė, kad didėjant radioterapijos dozei, ženkliai padidėjo ir radioatsparių ląstelių kiekis G2/M fazėje [27]. Ch.…”

Section: Diskusijaunclassified

Skirtingų Krūties Vėžio Ląstelių Linijų Atsparumo Radioterapijai Tyrimas

Laukaitienė¹,

Vaitkus²,

Savukaitytė³

et al. 2021

Health Sciences

View full text Add to dashboard Cite

Įvadas. Radioterapija yra vienas iš pagrindinių vėžio gydymo metodų, taikomų daugiau kaip pusei onkologinių pacientų. Manoma, kad pagrindinė onkologinės ligos pasikartojimo ir nesėkmingo gydymo priežastis yra vėžinių ląstelių atsparumas radioterapijai. Viena iš pagrindinių atsparumo radioterapijai priežasčių yra vėžinių ląstelių gebėjimas išvengti apoptozės. Manoma, kad ląstelės ciklas taip pat yra vienas iš procesų, turinčių reikšmės radioatsparumui. Šio tyrimo tikslas – įvertinti skirtingų krūties vėžio ląstelių linijų atsparumą radioterapijai, lyginant jų gyvybingumą, ląstelių pasiskirstymą tarp ciklo fazių ir apoptozės intensyvumą. Metodika. MCF-7 ir MDA-MB-231 ląstelių gyvybingumas buvo ištirtas, naudojant kolonijų formavimo testą. Ląstelės ciklo analizei buvo dažomos propidžio jodidu ir analizuojamos, naudojant tėkmės citometrą Muse Cell Analyzer. Apoptozės intensyvumui nustatyti naudotas aneksinas V ir Guava PCA tėkmės citometras. Rezultatai. Šiame tyrime nustatėme, kad MDA-MB-231 ląstelių gyvybingumas po radioterapijos poveikio buvo didesnis, nei MCF-7 ląstelių. Ciklo analizė parodė, kad po radioterapijos poveikio MCF-7 ląstelių ciklo sustabdymas vyko G0/G1 fazėje, o MDA-MB-231 ląstelių – G2/M fazėje. Po radioterapijos poveikio MCF-7 ląstelėse apoptozė prasidėjo anksčiau ir buvo intensyvesnė, o MDA-MB-231 ląstelės reagavo vėliau ir turėjo uždelstą apoptozinį atsaką. Išvados. MDA-MB-231 ląstelės buvo atsparesnės radioterapijai, negu MCF-7 ląstelės.

show abstract

“…Although patients with mCRPC can be treated with chemotherapeutic agents such as taxanes, immunotherapy, radiotherapy, or hormone therapy, these treatments can only improve the survival rate of patients by 2–4 months [ 10 , 11 ]. In addition to the aforementioned issues, PCa cells develop resistance to radiotherapy and chemotherapy, causing a clinical relapse [ 12 , 13 , 14 , 15 ].…”

Section: Introductionmentioning

confidence: 99%

Progress in Delivery of siRNA-Based Therapeutics Employing Nano-Vehicles for Treatment of Prostate Cancer

et al. 2020

View full text Add to dashboard Cite

Prostate cancer (PCa) accounts for a high number of deaths in males with no available curative treatments. Patients with PCa are commonly diagnosed in advanced stages due to the lack of symptoms in the early stages. Recently, the research focus was directed toward gene editing in cancer therapy. Small interfering RNA (siRNA) intervention is considered as a powerful tool for gene silencing (knockdown), enabling the suppression of oncogene factors in cancer. This strategy is applied to the treatment of various cancers including PCa. The siRNA can inhibit proliferation and invasion of PCa cells and is able to promote the anti-tumor activity of chemotherapeutic agents. However, the off-target effects of siRNA therapy remarkably reduce its efficacy in PCa therapy. To date, various carriers were designed to improve the delivery of siRNA and, among them, nanoparticles are of importance. Nanoparticles enable the targeted delivery of siRNAs and enhance their potential in the downregulation of target genes of interest. Additionally, nanoparticles can provide a platform for the co-delivery of siRNAs and anti-tumor drugs, resulting in decreased growth and migration of PCa cells. The efficacy, specificity, and delivery of siRNAs are comprehensively discussed in this review to direct further studies toward using siRNAs and their nanoscale-delivery systems in PCa therapy and perhaps other cancer types.

show abstract

Regulation of DNA damage response and cell cycle in radiation-resistant HL60 myeloid leukemia cells

Cited by 9 publications

References 20 publications

MiRNA‑30a‑3p inhibits metastasis and enhances radiosensitivity in esophageal carcinoma by targeting insulin‑like growth factor 1 receptor

MiRNA‑30a‑3p inhibits metastasis and enhances radiosensitivity in esophageal carcinoma by targeting insulin‑like growth factor 1 receptor

Skirtingų Krūties Vėžio Ląstelių Linijų Atsparumo Radioterapijai Tyrimas

Progress in Delivery of siRNA-Based Therapeutics Employing Nano-Vehicles for Treatment of Prostate Cancer

Contact Info

Product

Resources

About